Olezarsen Injection 80 mg/0.8 mL Suppliers & Bulk Manufacturers

Available Forms: Autoinjector (subcutaneous)

Available Strengths: 80 mg/0.8 mL

Reference Brands: Tryngolza (Ionis; Sobi outside the US)

Category: Heart Disorder

Olezarsen (Tryngolza, Ionis) is an antisense medicine that lowers triglycerides by reducing APOC3. It is approved in the US (December 2024) and EU (September 2025) for familial chylomicronaemia syndrome. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.

Product Description:

Olezarsen is an antisense oligonucleotide that binds the messenger RNA for apolipoprotein C-III (APOC3) in the liver, so less of the protein is made. APOC3 slows the clearance of triglyceride-rich particles; lowering it reduces triglycerides and, in trials, the number of pancreatitis attacks.

The US FDA approved olezarsen as Tryngolza in December 2024, and the European Commission followed in September 2025, for adults with familial chylomicronaemia syndrome (FCS) alongside diet. It is given as an 80 mg subcutaneous injection from an autoinjector. Ionis markets it in the US and Sobi outside the US. Ionis is also studying it in severe hypertriglyceridaemia, a much larger group of patients.

Sourcing and licensing notes. Olezarsen is patented and there is no generic. Plozasiran (Redemplo), an siRNA against the same target, is also listed on PharmaTradz. We confirm registration status for each destination before quoting.